Efficacy and safety profile of intra-articular administration of Jointex® in patients suffering from symptomatic hip osteoarthritis: An open, prospective study with a 12-month follow-up

European Journal of Inflammation

Volumn 9, Issue 3, 2011, Pages 269-276

  Migliore, Alberto ^a   Massafra, U ^a   Bizzi, E ^a   Vacca, F ^a   Martin Martin, L S ^b   Granata, M ^c   Tormenta, S ^a   Lagana B ^d  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b REGINA APOSTOLORUM HOSPITAL   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hip; Hyaluronic acid; Intra articular; Osteoarthritis; Ultrasound guidance

Indexed keywords

HYALURONIC ACID; JOINTEX; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIP OSTEOARTHRITIS; HIP RADIOGRAPHY; HUMAN; INFECTION; LEQUESNE INDEX; MALE; MULTICENTER STUDY; OUTPATIENT; PAIN ASSESSMENT; PROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; ULTRASOUND; VISUAL ANALOG SCALE;

EID: 84858626782     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1100900307     Document Type: Article

References (29)

1. Lawrence RC, Heimick CO, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778-99. (Pubitemid 28225778)
2. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000; 43:1905-15.
3. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2005; (2):CD005321.
4. Altman RD, Moskowitz R. Intra-articular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomised clinical trial. J Rheumatol 1998; 25:2203-12. (Pubitemid 28505869)
5. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26 week controlled trial of efficacy and safety in the osteoarthritis knee. Clin Ther 1998; 20:410-23. (Pubitemid 28343495)
6. Adams ME, Atkinson MH, Lussier A, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F alone, hylan G-F 20 with nonsteroidal antiinflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995; 3:213-26.
7. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (Hyalectin) in Osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthr Cartil 1993; 1:97-103.
8. Tamir E, Robinson D, Koren R, Agar G. Intra-articular hyaluronan for the treatment of osteoarthritis of the knee: A randomised, double blind, placebo controlled study. Clin Exp Rheumatol 2001; 19:265-70. (Pubitemid 32529818)
9. Pelletier JP, Martel-Pelletier J. The pathophysiology of osteoarthritis and the implication of the use of hyaloronan and hylan as therapeutic agents in viscosupplementation. J Rheumatol 1993; 39(S):19-24.
10. Pagnano M, Westrich G. Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthr Cartil 2005; 13:751-61. (Pubitemid 41263933)
11. van den Bekerom MP, Lamme B, Sermon A, Mulier M. What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg 2008; 128:815-23.
12. Migliore A, Tormenta S, Massafra U, Bizzi E, Iannessi F, Alimonti A, Granata M. Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice. Curr Med Res Opin 2008; 24:1309-16. (Pubitemid 351741562)
13. Migliore A, Martin Martin LS, Alimonti A, Valente C, Tormenta S. Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip. Osteoarthr Cartil 2003; 11/4:305-6. (Pubitemid 36410885)
14. Migliore A, Tormenta S, Martin Martin LS, Iannessi F, Massafra U, Carloni E, Monno D, Alimonti A, Granata M. The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol 2006; 25:389-93.
15. Migliore A, Tormenta S, Massafra U, Carloni E, Padalino C, Iannessi F, Alimonti A, Martin LS, Granata M. Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis. Osteoarthr Cartil 2005; 13:1126-27.
16. Jackson DW, Evans NA, and Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am 2002; 84A: 1522-27. (Pubitemid 35014700)
17. Grassi W, Farina A, Filippucci E, Cervini C. Sonographically guided procedures in rheumatology. Semin Arthritis Rheum 2001; 30:347-53. (Pubitemid 32298860)
18. Qvistgaard E, Kristoffersen H, Terslev L, Danneskiold-Samsoe B, Torp-pedersen S, Bliddal H. Guidance by ultrasound of intra-articular injections in the knee and hip joints. Osteoarthr Cartil 2001; 9:512-17. (Pubitemid 32842630)
19. Fernández López JC, Ruano-Ravina A. Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review. Osteoarthr Cartil 2006; 14:1306-11. (Pubitemid 44774446)
20. Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline.Osteoarth Cartil 2006; 14:163-70. (Pubitemid 43079313)
21. Tikiz C, Unlu Z, Sener A, Efe M. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumathol 2005; 24:244-50 (Pubitemid 40867947)
22. Conrozier T, Bertin P, Mathieu P, Chariot J, Bailleul F, Treves R, Vignon E, Chevalier X. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label, multicentre, pilot study. Clin Exp Rheumatol 2003; 21:605-10. (Pubitemid 37236454)
23. Altman R, Alarcon G. Appelrouth D, et al. The american College of Rheumatology criteria for the classification and reporting of Osteoarthritis of the Hip. Arthritis Rheum 1991; 34:505-14.
24. Kellgren JH, Lawrence JS. The Epidemiology of Chronic Rheumatism. Atlas of Standard Radiographs 1963; Vol. 2 Oxford, Blackwell Scientific.
25. Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol 1997; 24:779-81. (Pubitemid 27146100)
26. Helin-Salmivaara A, Saarelainen S, Grönroos JM, Vesalainen R, Klaukka T, Huupponen R. Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. Scand J Gastroenterol 2007; 42:923-32. (Pubitemid 47037118)
27. Meagher EA. Cardiovascular and renovascular implications of COX-2 inhibition. Curr Pharm Des 2004; 10:603-11. (Pubitemid 38292387)
28. Joshi GP, Gertler R, Fricker R. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg. 2007; 105:1793-804.
29. Kirwan J. Is there a place for intra-articular hyaluronate in osteoarthritis of the knee? Knee 2001; 8:93-101. (Pubitemid 32405246)